Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Sequestered Transscleral, Controlled-Release Topotecan Delivered From an Episcleral Reservoir in Retinoblastoma Eyes

NCT04156347 is registered in ClinicalTrials.gov with Targeted Therapy Technologies, LLC as lead sponsor.

NCT NCT04156347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04156347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Sequestered Transscleral, Controlled-Release Topotecan Delivered From an Episcleral Reservoir in Retinoblastoma Eyes
Lead sponsor
Targeted Therapy Technologies, LLC
Phase
Phase 1
Overall status
Unknown status
Start date
June 16, 2021
Completion date
October 14, 2024
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinoblastoma